CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Irbesartan

厄贝沙坦 杂质对照品Irbesartan Impurities

EP34 个杂质条目34 impurity entries

本页汇总 厄贝沙坦 的 34 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 34 impurity reference standards of Irbesartan with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 厄贝沙坦(Irbesartan)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment and Validation of four Nitrosamine Impurities Determination Method in Medicines of Valsartan, Losartan, and Irbesartan with HPLC-MS/MS (APCI)
    Iranian journal of pharmaceutical research : IJPR · 2021 · Khorolskiy M et al.  ·  PMID 34904007  ·  DOI
  2. 杂质研究Impurity studiesA validated stability-indicating liquid chromatographic method for determination of process related impurities and degradation behavior of Irbesartan in solid oral dosage
    Journal of advanced pharmaceutical technology & research · 2014 · Goswami N  ·  PMID 24695518  ·  DOI
  3. 杂质研究Impurity studiesA Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan
    Journal of chromatographic science · 2024 · Gopireddy RR et al.  ·  PMID 35830866  ·  DOI
  4. 分析方法Analytical MethodsSimultaneous Determination of Hydrochlorothiazide and Irbesartan from Pharmaceutical Dosage Forms with RP-HPLC
    Turkish journal of pharmaceutical sciences · 2020 · KurbanoĞlu S, Yarman A  ·  PMID 33177933  ·  DOI
  5. 分析方法Analytical MethodsSimultaneous Determination of Amlodipine and Irbesartan in their Pharmaceutical Formulations by Square-Wave Voltammetry
    Combinatorial chemistry & high throughput screening · 2022 · Palabıyık İM et al.  ·  PMID 33475067  ·  DOI

厄贝沙坦 —— 原料药与杂质对照品Irbesartan — drug substance & impurities

共 35 个条目(含原料药本体)35 items incl. the drug substance
Irbesartan structure
EP原料药 APIAPI
厄贝沙坦Irbesartan
Irbesartan
CAS No.138402-11-6
Chemical FormulaC25H28N6O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 1 (Irbesartan EP Impurity A) structure
EPA
厄贝沙坦杂质1 (厄贝沙坦EP杂质A)Irbesartan Impurity 1 (Irbesartan EP Impurity A)
Irbesartan Impurity 1 (Irbesartan EP Impurity A)
CAS No.748812-53-5
Chemical FormulaC25H30N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 5 structure
5
厄贝沙坦杂质5Irbesartan Impurity 5
Irbesartan Impurity 5
CAS No.1213252-83-5
Chemical FormulaC25H26N6O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 6 structure
6
厄贝沙坦杂质6Irbesartan Impurity 6
Irbesartan Impurity 6
CAS No.914465-68-2
Chemical FormulaC19H21N5O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 8 structure
8
厄贝沙坦杂质8Irbesartan Impurity 8
Irbesartan Impurity 8
CAS No.1312996-19-2
Chemical FormulaC21H20N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 10 structure
10
厄贝沙坦杂质10Irbesartan Impurity 10
Irbesartan Impurity 10
CAS No.1346598-52-4
Chemical FormulaC39H38N10O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 11 structure
11
厄贝沙坦杂质11Irbesartan Impurity 11
Irbesartan Impurity 11
CAS No.158778-58-6
Chemical FormulaC24H26N6O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 12 structure
12
厄贝沙坦杂质12Irbesartan Impurity 12
Irbesartan Impurity 12
CAS No.138401-24-8
Chemical FormulaC25H27N3O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 13 structure
13
厄贝沙坦杂质13Irbesartan Impurity 13
Irbesartan Impurity 13
CAS No.141745-71-3
Chemical FormulaC25H29N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 14 structure
14
厄贝沙坦杂质14Irbesartan Impurity 14
Irbesartan Impurity 14
CAS No.945540-26-1
Chemical FormulaC21H20N6O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 15 structure
15
厄贝沙坦杂质15Irbesartan Impurity 15
Irbesartan Impurity 15
CAS No.141745-36-0
Chemical FormulaC23H26N6O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 16 structure
16
厄贝沙坦杂质16Irbesartan Impurity 16
Irbesartan Impurity 16
CAS No.2045222-12-4
Chemical FormulaC25H28N6O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 19 Monomer structure
19
厄贝沙坦杂质19单体Irbesartan Impurity 19 Monomer
Irbesartan Impurity 19 Monomer
CAS No.138402-05-8
Chemical FormulaC11H18N2O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 19 structure
19
厄贝沙坦杂质19Irbesartan Impurity 19
Irbesartan Impurity 19
CAS No.151257-01-1
Chemical FormulaC11H18N2O·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 20 structure
20
厄贝沙坦杂质20Irbesartan Impurity 20
Irbesartan Impurity 20
CAS No.152708-24-2
Chemical FormulaC14H11N7
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 21 structure
21
厄贝沙坦杂质21Irbesartan Impurity 21
Irbesartan Impurity 21
CAS No.133690-91-2
Chemical FormulaC14H10N4
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 23 structure
23
厄贝沙坦杂质23Irbesartan Impurity 23
Irbesartan Impurity 23
CAS No.1079997-01-5
Chemical FormulaC26H30N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 25 structure
25
厄贝沙坦杂质25Irbesartan Impurity 25
Irbesartan Impurity 25
CAS No.2768787-11-5
Chemical FormulaC25H27N7O2
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 27 structure
27
厄贝沙坦杂质27Irbesartan Impurity 27
Irbesartan Impurity 27
CAS No.2763750-28-1
Chemical FormulaC14H12N4O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 28 structure
28
厄贝沙坦杂质28Irbesartan Impurity 28
Irbesartan Impurity 28
CAS No.2758005-15-9
Chemical FormulaC14H11N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 29 structure
29
厄贝沙坦杂质29Irbesartan Impurity 29
Irbesartan Impurity 29
CAS No.3092204-98-0
Chemical FormulaC28H22N8O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 40 structure
40
厄贝沙坦杂质40Irbesartan Impurity 40
Irbesartan Impurity 40
CAS No.16195-83-8
Chemical FormulaC6H10N2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 40 Monomer structure
40
厄贝沙坦杂质40 单体Irbesartan Impurity 40 Monomer
Irbesartan Impurity 40 Monomer
CAS No.49830-37-7
Chemical FormulaC6H10N2
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 41 structure
41
厄贝沙坦杂质41Irbesartan Impurity 41
Irbesartan Impurity 41
CAS No.194984-24-2
Chemical FormulaC11H18N2O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 42 structure
42
厄贝沙坦杂质42Irbesartan Impurity 42
Irbesartan Impurity 42
CAS No.886999-35-5
Chemical FormulaC44H42N6O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 43 structure
43
厄贝沙坦杂质43Irbesartan Impurity 43
Irbesartan Impurity 43
CAS No.224170-69-8
Chemical FormulaC38H44N6O10
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 44 structure
44
厄贝沙坦杂质44Irbesartan Impurity 44
Irbesartan Impurity 44
CAS No.160205-58-3
Chemical FormulaC31H36N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 45 structure
45
厄贝沙坦杂质45Irbesartan Impurity 45
Irbesartan Impurity 45
CAS No.15026-80-9
Chemical FormulaC11H19NO3
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 46 structure
46
厄贝沙坦杂质46Irbesartan Impurity 46
Irbesartan Impurity 46
CAS No.138402-10-5
Chemical FormulaC44H42N6O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 48 structure
48
厄贝沙坦杂质48Irbesartan Impurity 48
Irbesartan Impurity 48
CAS No.143618-44-4
Chemical FormulaC33H25N7
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 51 structure
51
厄贝沙坦杂质51Irbesartan Impurity 51
Irbesartan Impurity 51
CAS No.124806-66-2
Chemical FormulaC33H25N7
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 52 structure
52
厄贝沙坦杂质52Irbesartan Impurity 52
Irbesartan Impurity 52
CAS No.906474-58-6
Chemical FormulaC23H20N6O4
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 60 structure
60
厄贝沙坦杂质60Irbesartan Impurity 60
Irbesartan Impurity 60
CAS No.1111394-09-2
Chemical FormulaC21H25N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity 61 structure
61
厄贝沙坦杂质61Irbesartan Impurity 61
Irbesartan Impurity 61
CAS No.2045222-13-5
Chemical FormulaC25H27N3O
Purity>95%询价On request
10mg25mg50mg100mg
Irbesartan Impurity N69 structure
N69
氯沙坦杂质N69Irbesartan Impurity N69
Irbesartan Impurity N69
CAS No.147225-68-1
Chemical FormulaC14H13N5
Purity>95%现货In stock
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

厄贝沙坦 —— 研究文献与合成路线Irbesartan — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 厄贝沙坦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Irbesartan. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A validated stability-indicating liquid chromatographic method for determination of process related impurities and degradation behavior of Irbesartan in solid oral dosage
    Goswami N · Journal of advanced pharmaceutical technology & research · 2014 · 被引 6cited 6
  2. A Novel, Stability-indicating Method for Analyzing Degradation Impurities in Hydrochlorothiazide and Irbesartan Tablets Using RP-HPLC
    Shah T, Sharma S, Dhalani J · Current drug research reviews · 2026
  3. Stability indicating LC method for simultaneous determination of irbesartan and hydrochlorothiazide in pharmaceutical preparations
    Rane VP, Patil KR, Sangshetti JN, et al. · Journal of chromatographic science · 2010 · 被引 11cited 11
  4. A validated stability indicating HPTLC method for simultaneous estimation of irbesartan and hydrochlorothiazide
    Khodke AS, Potale LV, Damle MC, et al. · Pharmaceutical methods · 2010 · 被引 3cited 3
  5. Development and Validation of four Nitrosamine Impurities Determination Method in Medicines of Valsartan, Losartan, and Irbesartan with HPLC-MS/MS (APCI)
    Khorolskiy M, Ramenskaya G, Vlasov A, et al. · Iranian journal of pharmaceutical research : IJPR · 2021 · 被引 17cited 17
  6. Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MS(n), on-line H/D exchange and LC-NMR
    Shah RP, Sahu A, Singh S · Journal of pharmaceutical and biomedical analysis · 2010 · 被引 24cited 24

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF IRBESARTAN
    DIVI MURALI KRISHNA PRASAD, RAO MYSORE ASWATHA NARAYANA, NUTHI SURENDRA KALYAN, BANDARU YUGANDAR PHANIRAM · 公开号 US2011275828US2011275828 · 2011
  2. PROCESS FOR PREPARATION OF IRBESARTAN
    DESHPANDE PANDURANG BALWANT, LUTHRA PARVEN KUMAR, RATHOD DHIRAJ MOHANSINH, PATEL HITESH KANTILAL, et al. · 公开号 US2010113798US2010113798 · 2010
  3. Process for preparing trityl irbesartan and its use for synthesis of irbesartan
    RADL STANISLAV, STACH JAN · 公开号 SK50332006SK50332006 · 2006
  4. A new process for the preparation of irbesartan
    ZUPANCIC SILVO, BEVK DAVID, ZUPET ROK · 公开号 EP2194050EP2194050 · 2010
  5. Process for Preparing Irbesartan
    KUMAR UDHAYA, NEELA PRAVEEN KUMAR, PRADHAN NITIN SHARADCHANDRA, VALGEIRSSON JON · 公开号 US2010063299US2010063299 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

厄贝沙坦 杂质谱研究要点Irbesartan — impurity profiling notes

下面这些是拿到 厄贝沙坦 的 35 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 35 impurity entries for Irbesartan, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances